<DOC>
	<DOCNO>NCT01969851</DOCNO>
	<brief_summary>SP0966 exploratory study investigate safety efficacy Lacosamide ( LCM ) child epilepsy syndromes associate generalized seizure . LCM add current antiepileptic treatment .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Lacosamide Added Patients Current Therapy Patients Aged 1 Month Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures .</brief_title>
	<detailed_description>SP0966 Phase 2 , multicenter , open-label exploratory study design ass safety preliminary efficacy oral lacosamide adjunctive therapy epilepsy syndrome associate generalized seizure pediatric subject ≥1 month &lt; 18 year age .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>A sign informed consent obtain parent/legal representative assent obtain subject ( possible ) Subject caregiver willing able comply study requirement include maintain daily seizure diary Subject male female , ≥1 month &lt; 18 year age Subject diagnosis uncontrolled epilepsy generalize seizure ( Type II ) accord International Classification Epileptic Seizures ( 1981 ) . The underlying epilepsy syndrome document . Diagnosis establish clinical history Electroencephalogram ( EEG ) generalize spikewave discharge . Documentation EEG find generalize spike wave ( EEG record report ) require . The EEG perform 18 month prior Visit 1 ( change diagnosis seizure type time ) Subject must experience 2 event ( typical generalize seizure associate diagnosed epilepsy syndrome ) within 6week prospective Baseline Period Subject stable dosage regimen 1 3 antiepileptic drug ( AEDs ) . The daily dosage regimen concomitant AED therapy must keep constant period least 4 week prior Baseline Period Vagal nerve stimulation allow count concomitant AED . The vagus nerve stimulation ( VNS ) device must implant least 6 month Visit 1 , device setting must stable least 4 week Visit 1 keep stable Baseline Period Treatment Period . Use VNS device magnet allow Body weight Visit 1 least 4 kg infant . Females childbearing potential must negative pregnancy test Visit 1 Subjects West Syndrome eligible Baseline EEG demonstrate hypsarrhythmia despite treatment least 2 AEDs appropriate treatment syndrome Subject previously participate study , subject assign Lacosamide ( LCM ) previous LCM study , subject ever receive LCM Subject currently participate participate within last 2 month study investigational drug experimental device Subject history convulsive status epilepticus within 1 month prior Visit 1 Subject current previous diagnosis pseudoseizures , conversion disorder , nonepileptic ictal event could confuse seizure Subject exclusively typical absence ( Type IIA1 ) atypical absence ( Type IIA2 ) seizures ( generalized seizure type report ) , partialonset seizure ( Type I ) Subject medical psychiatric condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate study Subject ≥6 year age lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 Columbia Suicide Severity Rating Scale ( CSSRS ) Screening Subject know hypersensitivity component investigational medicinal product ( IMP ) Subject medical condition could reasonably expect interfere drug absorption , distribution , metabolism , excretion Subject know history severe anaphylactic reaction serious blood dyscrasia Subject history alcohol drug abuse within previous 2 year Subject acute subacutely progressive central nervous system disease . Subject epilepsy secondary progress cerebral disease progressively neurodegenerative disease ( malignant brain tumor Rasmussen Syndrome ) Subject alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin level ≥2x upper limit normal ( ULN ) alkaline phosphatase level ≥3x ULN Subject impair renal function ( ie , creatinine clearance lower 30 mL/min ) Visit 1 Subject sick sinus syndrome without pacemaker , second third degree atrioventricular ( AV ) block Subjects second thirddegree heart block exclude SP0966 ( NCT01969851 ) , without requirement rest Subject hemodynamically significant heart disease ( eg , heart failure ) Subject arrhythmic heart condition require medical therapy Subject know cardiac sodium channelopathy , Brugada syndrome Female subject pregnant nursing , and/or female subject childbearing potential surgically sterile practice 1 highly effective method contraception ( accord International Conference Harmonisation [ ICH ] guidance . Female subject childbearing potential take enzyme induce antiepileptic drug ( EI AEDs ) ( carbamazepine , phenytoin , barbiturate , primidone , topiramate , oxcarbazepine ) surgically sterile practice 1 highly effective method contraception accord World Health Organization recommendation ( ie , depot medroxyprogesterone acetate , norethisterone enantate , intrauterine device , combine injectables , progestogen implant ) administration enzyme induce antiepileptic drug ( EIAEDs ) practice 2 combine method contraception ( ie , combine hormonal contraception plus barrier method spermicidal agent ) , unless sexually abstinent , duration study Subject treat vigabatrin experienced vision loss . Subjects receive vigabatrin past must documentation assessment vision loss prior study entry documentation visual field test perform Subject treat felbamate experience serious toxicity issue ( define liver failure , aplastic anemia ) treatment . Subjects treat felbamate le 12 month exclude . Note : subject treat felbamate least 12 month experience serious toxicity issue eligible Subject take monoamine oxidase ( MAO ) inhibitor narcotic analgesic . Subject ketogenic specialize diet . If he/she specialize diet past , he/she must diet least 2 month prior Screening Visit ( Visit 1 ) Subject primary generalize tonicclonic seizure diagnosis idiopathic generalize epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Children</keyword>
</DOC>